Annexon (ANNX) – Analysts’ Weekly Ratings Changes

Several analysts have recently updated their ratings and price targets for Annexon (NASDAQ: ANNX):

• 7/21/2026 – Annexon is now covered by Citigroup Inc.. They set a “market underperform” rating on the stock.
• 7/21/2026 – Annexon is now covered by Citizens Jmp. They set a “market underperform” rating and a $3.00 price target on the stock.
• 7/20/2026 – Annexon had its “buy” rating reaffirmed by HC Wainwright. They now have a $14.00 price target on the stock.
• 7/17/2026 – Annexon had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/15/2026 – Annexon had its price target raised by Needham & Company LLC from $11.00 to $25.00. They now have a “buy” rating on the stock.
• 7/13/2026 – Annexon had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 7/12/2026 – Annexon was downgraded by Wall Street Zen from “hold” to “sell”.

Insider Activity

In related news, Director Muneer A. Satter acquired 613,497 shares of the business’s stock in a transaction that occurred on Thursday, May 28th. The shares were bought at an average cost of $5.41 per share, with a total value of $3,319,018.77. Following the completion of the purchase, the director directly owned 10,342,134 shares in the company, valued at $55,950,944.94. The trade was a 6.31% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, Director William H. Carson purchased 8,000 shares of the business’s stock in a transaction on Monday, May 11th. The shares were acquired at an average price of $5.78 per share, for a total transaction of $46,240.00. Following the completion of the acquisition, the director directly owned 78,405 shares in the company, valued at approximately $453,180.90. This represents a 11.36% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 10.31% of the stock is currently owned by company insiders.

Annexon Inc is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company’s research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies.

At the core of Annexon’s pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications.